Abstract
Gentamicin pharmacokinetics was examined in a group of 47 patients with stable renal function treated an average of 10 days for severe infection. Serum concentrations rose continually during treatment, and declined in two phases after the drug was stopped, with a mean half-life of 112hr (range 27–693 hr) in the second phase. A two-compartment model was used to describe the biphasic decline in serum concentrations and to calculate the amount of drug in the tissue compartment at all times during and after treatment. Predicted tissue amounts of gentamicin rose continually on multiple dosing in all patients. In six patients who died, postmortem tissues were obtained to quantitate recovery. In all cases, the predicted amount of gentamicin in tissues was in close agreement with the amount recovered at autopsy. Tissue distribution and accumulation constitute a major reason for variability in gentamicin pharmacokinetics and explain both the rising peak and trough serum concentrations and the prolonged detection of gentamicin in serum and urine after the drug is stopped.
Similar content being viewed by others
References
R. E. Cutler, A. M. Gyselynck, W. P. Fleet, and A. W. Forrey. Correlation of serum creatinine concentration and gentamicin half-life.J. Am. Med. Assoc. 219:1037–1041 (1972).
D. Kaye, M. E. Levison, and E. D. Labovitz. The unpredictability of serum concentrations of gentarnicin: Pharmacokinetics of gentamicin in patients with normal and abnormal renal function.J. Infect. Dis. 130:150–154 (1974).
M. Barza, R. B. Brown, D. Shen, M. Gibaldi, and L. Weinstein. Predictability of blood levels of gentamicin in man.J. Infect. Dis. 132:165–174 (1975).
J. G. Dahlgren, E. T. Anderson, and W. L. Hewitt. Gentamicin blood levels: A guide to nephrotoxicity.Antimicrob. Agents Chemother. 8:58–62 (1975).
G. Kahlmeter and C. Kamme. Prolonged excretion of gentarnicin in a patient with unimpaired renal function.Lancet 1:286 (1975).
J. J. Schentag and W. J. Jusko. Gentamicin persistence in the body.Lancet 1:486 (1977).
J. J. Schentag, W. J. Jusko, M. E. Plaut, T. J. Cumbo, J. W. Vance, and E. Abrutyn. Tissue persistence of gentamicin in man.J. Am. Med. Assoc. 238:327–329 (1977).
K. Siersbaek-Nielsen, J. M. Hansen, J. Kampmann, and M. Kristensen. Rapid evaluation of creatinine clearance.Lancet 1:1133 (1971).
R. A. Chan, E. J. Benner, and P. D. Hoeprich. Gentamicin therapy in renal failure: A nomogram for dosage.Ann. Intern. Med. 76:773–778 (1972).
R. E. Winters, K. D. Litwack, and W. L. Hewitt. Relation between dose and levels of gentamicin in blood.J. Infect. Dis. Suppl. 124:S90-S95 (1971).
C. M. Kunin. Binding of antibiotics to tissue homogenates.J. Infect. Dis. 121:55–64 (1970).
C. M. Metzler.NONLIN: A Computer Program for Parameter Estimation in Nonlinear Situations, Technical Report No. 7292/69/7292/005, Upjohn Company, Kalamazoo, Mich., Nov. 25, 1969.
M. Gibaldi and D. Perrier.Drugs and the Pharmaceutical Sciences, Vol. 1:Pharmacokinetics, J. Swarbrick (ed.), Marcel Dekker, New York, 1975, p. 119.
B. J. Devine, Gentamicin Therapy.Drug Intell. Clin. Pharmacol. 8:650–655 (1974).
J. J. Schentag and W. J. Jusko. Renal clearance and tissue accumulation of gentamicin.Clin. Pharmacol. Ther. in press (1977).
C. Q. Edwards, C. R. Smith, K. L. Baughman, J. F. Roger, and P. S. Leitman. Concentrations of gentamicin and amikacin in human kidneys.Antimicrob. Agents Chemother. 9:925–927 (1976).
F. C. Luft and S. A. Kleit. Renal parenchymal accumulation of aminoglycoside antibiotics in rats.J. Infect. Dis. 130:656–659 (1974).
D. Lalka, W. J. Jusko, and T. J. Bardos. Reactions of 2,2-dimethylaziridine-type alkylating agents in biological systems. II. Comparative pharmacokinetics in dogs.J. Pharm. Sci. 65:230–235 (1975).
Author information
Authors and Affiliations
Additional information
Supported in part by Grant GM 20852 from the National Institutes of General Medical Sciences, NIH.
Rights and permissions
About this article
Cite this article
Schentag, J.J., Jusko, W.J., Vance, J.W. et al. Gentamicin disposition and tissue accumulation on multiple dosing. Journal of Pharmacokinetics and Biopharmaceutics 5, 559–577 (1977). https://doi.org/10.1007/BF01059684
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01059684